ATE319428T1 - Zusammensetzung zur behandlung von entzündlichen erkrankungen - Google Patents
Zusammensetzung zur behandlung von entzündlichen erkrankungenInfo
- Publication number
- ATE319428T1 ATE319428T1 AT01991836T AT01991836T ATE319428T1 AT E319428 T1 ATE319428 T1 AT E319428T1 AT 01991836 T AT01991836 T AT 01991836T AT 01991836 T AT01991836 T AT 01991836T AT E319428 T1 ATE319428 T1 AT E319428T1
- Authority
- AT
- Austria
- Prior art keywords
- vesicle
- treatment
- composition
- inflammatory diseases
- mole percent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/70—Nanostructure
- Y10S977/788—Of specified organic or carbon-based composition
- Y10S977/797—Lipid particle
- Y10S977/798—Lipid particle having internalized material
- Y10S977/799—Containing biological material
- Y10S977/801—Drug
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/906—Drug delivery
- Y10S977/907—Liposome
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP00204372 | 2000-12-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE319428T1 true ATE319428T1 (de) | 2006-03-15 |
Family
ID=8172392
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01991836T ATE319428T1 (de) | 2000-12-07 | 2001-12-07 | Zusammensetzung zur behandlung von entzündlichen erkrankungen |
Country Status (11)
Country | Link |
---|---|
US (1) | US7955618B2 (de) |
EP (1) | EP1347743B1 (de) |
JP (1) | JP4623931B2 (de) |
AT (1) | ATE319428T1 (de) |
AU (2) | AU2002231697B2 (de) |
CA (1) | CA2430897C (de) |
DE (1) | DE60117858T2 (de) |
DK (1) | DK1347743T3 (de) |
ES (1) | ES2260321T3 (de) |
PT (1) | PT1347743E (de) |
WO (1) | WO2002045688A2 (de) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002045688A2 (en) | 2000-12-07 | 2002-06-13 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
US7635463B2 (en) * | 2002-02-27 | 2009-12-22 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials |
EP1371362A1 (de) * | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Zusammensetzung zur Behandlung entzündlicher Erkrankungen |
EP1393720A1 (de) * | 2002-08-27 | 2004-03-03 | Universiteit Utrecht | Vesikel enthaltend Corticosteroide zur Behandlung von Krebs |
WO2005011633A1 (ja) * | 2003-08-01 | 2005-02-10 | National Institute Of Advanced Industrial Science And Technology | 標的指向性リポソームを含む炎症性疾患治療薬または診断薬 |
US20050255154A1 (en) | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
WO2006027786A2 (en) | 2004-09-09 | 2006-03-16 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Use of liposomal glucocorticoids for treating inflammatory states |
AU2006270165B2 (en) | 2005-07-14 | 2010-03-11 | Neothetics, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
ES2398480T3 (es) * | 2006-10-17 | 2013-03-19 | Lithera, Inc. | Procedimientos, composiciones, y formulaciones para el tratamiento de la enfermedad ocular tiroidea |
US20090155207A1 (en) * | 2007-11-29 | 2009-06-18 | Hariri Robert J | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders |
EP2127639A1 (de) | 2008-05-26 | 2009-12-02 | Universiteit Utrecht Holding B.V. | Corticosteroid enthaltende Liposomen zur Behandlung von kardiovaskulären Erkrankungen |
US20100016265A1 (en) * | 2008-07-16 | 2010-01-21 | Qaiser Yusuf | Anti-inflammatory composition and method for preparation |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
GB2487868B (en) * | 2010-01-15 | 2014-12-10 | Neothetics Inc | Lyophilized cake formulations |
TW201231042A (en) | 2010-11-24 | 2012-08-01 | Lithera Inc | Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging |
DK2773325T3 (en) * | 2011-11-04 | 2019-01-14 | Enceladus Pharmaceuticals B V | LIPOSOMAL CORTICOSTEROIDS FOR TREATMENT OF INFLAMMATORY DISORDERS BY HUMANS |
US9186326B2 (en) * | 2014-07-21 | 2015-11-17 | Kimia Zist Parsian (Kzp) | Method and system for synthesizing nanocarrier based long acting drug delivery system for dexamethasone |
WO2017048860A1 (en) * | 2015-09-14 | 2017-03-23 | Vgsk Technologies, Inc. | A sterically stabilized carrier for subcutaneous, sublingual and oral therapeutics, compositions and methods for treating a mammal |
EP3448359B1 (de) | 2016-04-29 | 2023-06-07 | Laurentia Holding B.V. | Liposomale corticosteroide zur topischen injektion in entzündete läsionen oder bereiche |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2002185A (en) * | 1930-06-26 | 1935-05-21 | Prosperity Co Inc | Garment or ironing press |
GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
US4522803A (en) * | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
US4994443A (en) * | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5192528A (en) * | 1985-05-22 | 1993-03-09 | Liposome Technology, Inc. | Corticosteroid inhalation treatment method |
IL79114A (en) | 1985-08-07 | 1990-09-17 | Allergan Pharma | Method and composition for making liposomes |
DE3542773A1 (de) * | 1985-12-04 | 1987-06-11 | Roehm Pharma Gmbh | Hautwirksame pharmaka mit liposomen als wirkstofftraeger |
US4818537A (en) * | 1986-10-21 | 1989-04-04 | Liposome Technology, Inc. | Liposome composition for treating dry eye |
IL91664A (en) * | 1988-09-28 | 1993-05-13 | Yissum Res Dev Co | Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release |
US5139803A (en) * | 1989-02-09 | 1992-08-18 | Nabisco, Inc. | Method and liposome composition for the stabilization of oxidizable substances |
FR2648462B1 (fr) * | 1989-06-15 | 1994-01-28 | Oreal | Procede pour ameliorer l'efficacite therapeutique de corticosteroides liposolubles et composition pour la mise en oeuvre de ce procede |
US5356633A (en) * | 1989-10-20 | 1994-10-18 | Liposome Technology, Inc. | Method of treatment of inflamed tissues |
US5585112A (en) * | 1989-12-22 | 1996-12-17 | Imarx Pharmaceutical Corp. | Method of preparing gas and gaseous precursor-filled microspheres |
US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
US5989586A (en) | 1992-10-05 | 1999-11-23 | Cygnus, Inc. | Two-phase matrix for sustained release drug delivery device |
CA2120197A1 (en) * | 1993-04-02 | 1994-10-03 | Kenji Endo | Stable aqueous dispersions containing liposomes |
JPH07316040A (ja) * | 1994-03-29 | 1995-12-05 | Res Dev Corp Of Japan | 再構成リポソームと物質導入方法 |
US5786344A (en) * | 1994-07-05 | 1998-07-28 | Arch Development Corporation | Camptothecin drug combinations and methods with reduced side effects |
JPH08198777A (ja) * | 1995-01-25 | 1996-08-06 | Taisho Pharmaceut Co Ltd | 注射用脂肪乳剤 |
EP0811179B1 (de) * | 1995-12-15 | 2006-03-01 | Koninklijke Philips Electronics N.V. | Flüssigkristallanzeigevorrichtung |
JPH09278672A (ja) * | 1996-04-12 | 1997-10-28 | Green Cross Corp:The | 薬物含有脂肪乳剤 |
EP0850646B1 (de) * | 1996-06-18 | 2007-12-26 | Kyowa Hakko Kogyo Co., Ltd. | Liposomale zubereitungen von indolocarbazol-derivaten |
ES2208946T3 (es) * | 1996-08-23 | 2004-06-16 | Sequus Pharmaceuticals, Inc. | Liposomas que contienen un compuesto de cisplatino. |
US6090800A (en) * | 1997-05-06 | 2000-07-18 | Imarx Pharmaceutical Corp. | Lipid soluble steroid prodrugs |
US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US5758659A (en) | 1997-03-26 | 1998-06-02 | Thompson; Robert B. | Wound tab condom and method of application |
US20020159951A1 (en) | 1997-05-06 | 2002-10-31 | Unger Evan C. | Novel targeted compositions for diagnostic and therapeutic use |
AU6974798A (en) | 1997-05-06 | 1998-11-27 | Imarx Pharmaceutical Corp. | Novel prodrugs comprising fluorinated amphiphiles |
US6506783B1 (en) * | 1997-05-16 | 2003-01-14 | The Procter & Gamble Company | Cancer treatments and pharmaceutical compositions therefor |
US6316260B1 (en) * | 1997-08-22 | 2001-11-13 | Bernina Biosystems Gmbh | Tetraether lipid derivatives and liposomes and lipid agglomerates containing tetraether lipid derivatives, and use thereof |
EP1044679B1 (de) * | 1998-11-02 | 2012-12-26 | Terumo Kabushiki Kaisha | Stabile Liposomen für Gezielte Arzneimittlelgabe |
PL193824B1 (pl) | 1998-12-23 | 2007-03-30 | Idea Ag | Preparat zawierający środki penetrujące, sposób wytwarzania preparatu zawierającego środki penetrujące oraz zastosowanie preparatu do wytwarzania leku |
US6270806B1 (en) * | 1999-03-03 | 2001-08-07 | Elan Pharma International Limited | Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions |
EP1190706B1 (de) | 1999-06-25 | 2009-05-06 | Terumo Kabushiki Kaisha | Liposome |
KR100758158B1 (ko) * | 1999-07-14 | 2007-09-12 | 알자 코포레이션 | 중성 지질중합체 및 그를 함유하는 리포솜 조성물 |
EP1072617A1 (de) | 1999-07-30 | 2001-01-31 | Universiteit van Utrecht | Temperaturempfindliche Polymere |
US6511676B1 (en) * | 1999-11-05 | 2003-01-28 | Teni Boulikas | Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes |
US20030050236A1 (en) * | 2000-08-15 | 2003-03-13 | The University Of Chicago | Compounds that enhance tumor death |
TWI230616B (en) * | 2000-09-25 | 2005-04-11 | Ind Tech Res Inst | Liposome for incorporating large amounts of hydrophobic substances |
WO2002045688A2 (en) | 2000-12-07 | 2002-06-13 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
US20050152962A1 (en) | 2002-06-12 | 2005-07-14 | Metselaar Josbert M. | Composition for treatment of inflammatory disorders |
EP1371362A1 (de) | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Zusammensetzung zur Behandlung entzündlicher Erkrankungen |
EP1393720A1 (de) | 2002-08-27 | 2004-03-03 | Universiteit Utrecht | Vesikel enthaltend Corticosteroide zur Behandlung von Krebs |
-
2001
- 2001-12-07 WO PCT/EP2001/014633 patent/WO2002045688A2/en active IP Right Grant
- 2001-12-07 ES ES01991836T patent/ES2260321T3/es not_active Expired - Lifetime
- 2001-12-07 AU AU2002231697A patent/AU2002231697B2/en not_active Ceased
- 2001-12-07 PT PT01991836T patent/PT1347743E/pt unknown
- 2001-12-07 DE DE60117858T patent/DE60117858T2/de not_active Expired - Lifetime
- 2001-12-07 CA CA2430897A patent/CA2430897C/en not_active Expired - Lifetime
- 2001-12-07 AU AU3169702A patent/AU3169702A/xx active Pending
- 2001-12-07 AT AT01991836T patent/ATE319428T1/de active
- 2001-12-07 DK DK01991836T patent/DK1347743T3/da active
- 2001-12-07 JP JP2002547474A patent/JP4623931B2/ja not_active Expired - Fee Related
- 2001-12-07 EP EP01991836A patent/EP1347743B1/de not_active Expired - Lifetime
-
2003
- 2003-06-05 US US10/455,257 patent/US7955618B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1347743A2 (de) | 2003-10-01 |
JP2004517835A (ja) | 2004-06-17 |
EP1347743B1 (de) | 2006-03-08 |
US20040037875A1 (en) | 2004-02-26 |
CA2430897C (en) | 2010-11-16 |
WO2002045688A2 (en) | 2002-06-13 |
JP4623931B2 (ja) | 2011-02-02 |
US7955618B2 (en) | 2011-06-07 |
DE60117858T2 (de) | 2006-11-30 |
PT1347743E (pt) | 2006-06-30 |
DK1347743T3 (da) | 2006-07-03 |
CA2430897A1 (en) | 2002-06-13 |
AU3169702A (en) | 2002-06-18 |
ES2260321T3 (es) | 2006-11-01 |
AU2002231697B2 (en) | 2006-09-07 |
WO2002045688A3 (en) | 2002-11-14 |
DE60117858D1 (de) | 2006-05-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE319428T1 (de) | Zusammensetzung zur behandlung von entzündlichen erkrankungen | |
ATE406873T1 (de) | Zusammensetzung zur behandlung entzündlicher erkrankungen | |
Dokka et al. | Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes | |
FI971494A (fi) | Eetterilipidiloposomit sekä niiden terapeuttinen käyttö | |
DE69033856T2 (de) | Verabreichungssystem für phospholipide | |
AU2003258686A1 (en) | Vesicle-encapsulated corticosteroids for the treatment of cancer | |
ES2173420T3 (es) | Comprimidos que contienen un antibiotico de beta-lactamico y procedimiento para su produccion. | |
AU2003304237A1 (en) | Gel-stabilized nanoparticulate active agent compositions | |
AR015919A1 (es) | Formas de dosificacion de liberacion sostenida de sertralina, sales de sertralina ,composicion farmaceutica, procedimiento depreparacion y su uso en terapias. | |
TR200101307T2 (tr) | Antranilik asit amidler ve ilaç olarak kullanılmaları. | |
NO980047L (no) | Blanding for tildeling av et polart medikament i kolon | |
DE69531701D1 (de) | Sphingosome mit verbesserter arzneistoffabgage | |
AU3559895A (en) | Polyethylene glycol modified ceramide lipids and liposome uses thereof | |
FI956014A (fi) | Nona- ja dekapeptidien käyttö lääkkeen valmistamiseksi AIDS-sairauden hoitoon | |
ATE310512T1 (de) | Verwendung von lipoxinen zur inhibierung von tnf- alpha initiierter gegenreaktion | |
NZ335125A (en) | Carriers containing an etherlipid/complementarily shape lipid combination and therapeutic uses thereof | |
ES8707111A1 (es) | Procedimiento para obtencion de un preparado farmaceutico para tratamiento terapeutico de enfermedades reumaticas. | |
ZA965666B (en) | Preparations and methods for the treatment of t cell mediated diseases | |
ES2084348T3 (es) | N-((4,5-dihidroxi- y 4,5,8-trihidroxi-9,10-dihidro-9,10-dioxo-2-antracen-il)carbonil)aminoacidos utiles en la terapia de afecciones osteoarticulares. | |
GEP20053512B (en) | S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders. | |
YU24603A (sh) | Novi farmaceutski preparati koji sadrže epinastin i pseudoefedrin | |
ATE384133T1 (de) | Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen | |
Cabezas Llobet | Therapeutic potential of pituitary adenylate cyclase-activating polypeptide and epigallocatechin gallate in motor and cognitive deficits of Huntington's disease models | |
Whitmore | Antitumor activity of the LPD lipopolyplex prepared with immunostimulatory CpG DNA | |
邱信芳 et al. | Gene Therapy for Genetic Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1347743 Country of ref document: EP |
|
EEIH | Change in the person of patent owner |